Keyword: Tango Therapeutics

The agreement gives Gilead the option to pick up the worldwide rights to five targets discovered and validated by Tango.

Atara hires ex-Genentech SVP to lead R&D, Semma names former Novartis CAR-T developer as CEO, and GSK's CFO heads for the exit.

AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.

Allergan CFO Hilado and Gilead COO Young will retire from their positions and Rubius has poached a GSK SVP as CMO.